Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | ADH7 | P40394 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 5/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL86734 | 0.86 | — | — | |
| SCHEMBL30097899 | 0.82 | ESR1 (0.32) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6853690 | 0.82 | ADH1B (0.41) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL20869047 | 0.79 | — | — | |
| SCHEMBL11796470 | 0.78 | ADH1A (0.39) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL5680442 | 0.78 | ESR1 (0.31) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12555120 | 0.78 | ADH1B (0.39) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL11903717 | 0.77 | ADH1A (0.47) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL11904004 | 0.77 | ADH1C (0.47) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL15827349 | 0.77 | EPHX2 (0.33) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981705-B | Method for preparing cyclohexane dimethylamine | 万华化学集团股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-110981705-A | Method for preparing cyclohexane dimethylamine | 万华化学集团股份有限公司 | 2020-04-10 | — | — | CN | disclosed |
| EP-1764353-B1 | Improved metal-ligand complex catalysed processes | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-1204623-B1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1764353-A1 | Improved metal-ligand complex catalysed processes | Union Carbide Chemical & Plastics Technology Corporation (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1711617-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICS COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005064008-A9 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-1204623-A2 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2002-05-15 | — | — | EP | disclosed |
| US-6252121-B1 | SEPARATION OF CYCLIC REACTANTS, CORRESPONDING PRODUCTS, NONPOLAR SOLVENT, ORGANOPHOSPHORUS LIGANDS AND CATALYST COMPLEX MATERIALS FROM MULTIPHASE REACTION PRODUCT FLUID HAVING POLAR AND NONPOLAR PHASES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION | 2001-06-26 | — | — | US | disclosed |
| WO-2001007382-A2 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | ADH1B 1807/4885ADH1C 3921/4885ADH1A 3563/4885 |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | ADH1B 1312/4885ADH1C 1946/4885ADH1A 1924/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | ADH1B 1770/4885ADH1C 3873/4885ADH1A 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.